BidaskClub upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a strong-buy rating in a research note released on Saturday.

Several other research analysts have also recently issued reports on SGMO. Zacks Investment Research cut shares of Sangamo Therapeutics from a hold rating to a sell rating in a report on Friday, January 18th. ValuEngine cut shares of Sangamo Therapeutics from a strong-buy rating to a buy rating in a report on Saturday, November 10th. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the stock a hold rating in a report on Monday, November 19th. Guggenheim began coverage on shares of Sangamo Therapeutics in a report on Tuesday, October 9th. They set a buy rating and a $18.00 price target for the company. Finally, JPMorgan Chase & Co. cut shares of Sangamo Therapeutics from an overweight rating to a neutral rating and cut their price target for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Sangamo Therapeutics currently has an average rating of Buy and an average price target of $18.83.

NASDAQ SGMO opened at $12.30 on Friday. The stock has a market cap of $1.29 billion, a P/E ratio of -17.57 and a beta of 2.84. Sangamo Therapeutics has a 52-week low of $9.00 and a 52-week high of $27.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.32 and a quick ratio of 6.32.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. The firm had revenue of $23.56 million during the quarter, compared to analysts’ expectations of $26.96 million. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The firm’s revenue for the quarter was up 99.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.15) earnings per share. As a group, sell-side analysts predict that Sangamo Therapeutics will post -0.72 EPS for the current fiscal year.

In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 12,250 shares in the company, valued at $122,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 25,000 shares of company stock worth $281,500 over the last 90 days. 1.20% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its position in Sangamo Therapeutics by 47.6% during the fourth quarter. Rhumbline Advisers now owns 134,623 shares of the biopharmaceutical company’s stock worth $1,545,000 after buying an additional 43,418 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in Sangamo Therapeutics during the fourth quarter worth about $102,000. Merriman Wealth Management LLC acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Sangamo Therapeutics by 29.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 1,552 shares during the last quarter. Finally, Bourgeon Capital Management LLC grew its position in shares of Sangamo Therapeutics by 49.4% in the fourth quarter. Bourgeon Capital Management LLC now owns 17,400 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 5,750 shares during the last quarter. Institutional investors own 62.90% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Article: Analyst Ratings Trading

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.